CPP
MCID: CNT075
MIFTS: 53

Central Precocious Puberty (CPP)

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Central Precocious Puberty

MalaCards integrated aliases for Central Precocious Puberty:

Name: Central Precocious Puberty 43 58 36 29 39 17
Cpp 43 58
Gonadotropin-Dependent Precocious Puberty 43
Gonadotropin-Dependant Precocious Puberty 58
Precocious Puberty, Central 70

Characteristics:

Orphanet epidemiological data:

58
central precocious puberty
Inheritance: Autosomal dominant,Not applicable; Age of onset: Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases
Rare endocrine diseases


External Ids:

KEGG 36 H02018
ICD10 via Orphanet 33 E22.8
UMLS via Orphanet 71 C0342543
Orphanet 58 ORPHA759
UMLS 70 C0342543

Summaries for Central Precocious Puberty

MedlinePlus Genetics : 43 Central precocious puberty is a condition that causes early sexual development in girls and boys. While puberty normally starts between ages 8 and 13 in girls and between ages 9 and 14 in boys, girls with central precocious puberty begin exhibiting signs before age 8, and boys with this disorder begin before age 9. Signs of puberty include development of pubic and underarm hair, a rapid increase in height (commonly referred to as a "growth spurt"), acne, and underarm odor. Girls also develop breasts and begin their menstrual periods. Boys have growth of the penis and testes and deepening of the voice. Because of the early growth spurt, children with central precocious puberty may be taller than their peers; however, they may stop growing abnormally early. Without proper treatment, some affected individuals are shorter in adulthood compared with other members of their family. Developing ahead of their peers can be emotionally difficult for affected individuals and may lead to psychological and behavioral problems.

MalaCards based summary : Central Precocious Puberty, also known as cpp, is related to hypothalamic hamartomas and precocious puberty. An important gene associated with Central Precocious Puberty is KISS1R (KISS1 Receptor), and among its related pathways/superpathways are Peptide hormone metabolism and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Leuprolide and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and pineal, and related phenotypes are isosexual precocious puberty and increased circulating gonadotropin level

KEGG : 36 Central precocious puberty is caused by early maturation of the hypothalamic-pituitary-gonadal axis. Recently, kisspeptin receptor (KISS1R) and its ligand, kisspeptin, were described as an excitatory neuroregulator system for the secretion of gonadotropin-releasing hormone (GnRH). Mutations of the KISS1R gene were identified in patients with impaired pubertal development. It has also been reported that central precocious puberty caused by mutations in the imprinted gene MKRN3.

Related Diseases for Central Precocious Puberty

Diseases in the Precocious Puberty family:

Precocious Puberty, Central, 1 Precocious Puberty, Central, 2
Central Precocious Puberty Secondary Central Precocious Puberty
Rare Precocious Puberty

Diseases related to Central Precocious Puberty via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 355)
# Related Disease Score Top Affiliating Genes
1 hypothalamic hamartomas 31.9 KISS1R KISS1 GNRH1
2 precocious puberty 31.8 MKRN3 KISS1R KISS1 GNRH1 GH1
3 idiopathic central precocious puberty 31.7 MKRN3 KISS1R KISS1 IGF1 DLK1
4 maternal uniparental disomy 30.4 GNRH1 DLK1
5 hypogonadotropic hypogonadism 30.3 LEP KISS1R KISS1 GNRH1
6 hyperandrogenism 30.2 IGFBP3 IGF1 GNRH1
7 hyperprolactinemia 30.2 IGF1 GNRH1 GH1
8 hypogonadism 30.2 LEP KISS1R KISS1 IGF1 GNRH1
9 temple syndrome 30.1 MKRN3 KISS1 DLK1
10 slipped capital femoral epiphysis 30.1 IGFBP3 IGF1
11 intracranial hypertension, idiopathic 30.1 LEP IGF1
12 normosmic congenital hypogonadotropic hypogonadism 30.1 KISS1R KISS1 GNRH1
13 precocious puberty, male-limited 30.0 MKRN3 KISS1R KISS1 GNRH1
14 pituitary tumors 30.0 IGF1 GH1
15 pseudohypoparathyroidism, type ia 30.0 IGF1 GH1
16 premature menopause 29.9 KISS1R KISS1 IGF1 GNRH1
17 cryptorchidism, unilateral or bilateral 29.8 MKRN3 KISS1R KISS1 IGF1 GNRH1
18 pituitary adenoma 29.8 IGF1 GNRH1 GH1
19 craniopharyngioma 29.8 IGF1 GNRH1 GH1
20 pituitary adenoma, prolactin-secreting 29.7 IGF1 GNRH1 GH1
21 insulin-like growth factor i 29.7 LEP IGFBP3 IGF1 GH1
22 fibrous dysplasia 29.7 IGF1 GH1
23 mccune-albright syndrome 29.6 IGFBP3 IGF1 GH1
24 polycystic ovary syndrome 29.6 LEP IGFBP3 IGF1 GNRH1 GH1
25 silver-russell syndrome 1 29.5 IGFBP3 IGF1 DLK1
26 cerebral palsy 29.4 LEP IGFBP3 IGF1
27 kallmann syndrome 29.4 MKRN3 LEP KISS1R KISS1 GNRH1
28 empty sella syndrome 29.4 IGFBP3 IGF1 GNRH1 GH1
29 conn's syndrome 29.3 LEP IGF1 GNRH1 GH1
30 septooptic dysplasia 29.1 IGFBP3 IGF1 GNRH1 GH1
31 hypothyroidism 29.0 LEP IGFBP3 IGF1 GNRH1 GH1
32 turner syndrome 29.0 LEP IGFBP3 IGF1 GH1
33 body mass index quantitative trait locus 11 28.9 LEP IGFBP3 IGF1 GH1 DLK1
34 prader-willi syndrome 28.8 MKRN3 LEP IGFBP3 IGF1 GNRH1 GH1
35 hyperinsulinism 28.7 LEP IGFBP3 IGF1 GNRH1 GH1
36 precocious puberty, central, 2 11.5
37 papilloma of choroid plexus 11.5
38 precocious puberty, central, 1 11.4
39 secondary central precocious puberty 11.3
40 chondrocalcinosis 2 11.1
41 atypical choroid plexus papilloma 11.0
42 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.7
43 body mass index quantitative trait locus 1 10.7
44 lipoid congenital adrenal hyperplasia 10.6
45 growth hormone deficiency 10.4
46 hydrocephalus 10.4
47 acne 10.4
48 neurofibromatosis 10.4
49 head injury 10.3
50 williams-beuren syndrome 10.3

Graphical network of the top 20 diseases related to Central Precocious Puberty:



Diseases related to Central Precocious Puberty

Symptoms & Phenotypes for Central Precocious Puberty

Human phenotypes related to Central Precocious Puberty:

58 31 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 isosexual precocious puberty 58 31 obligate (100%) Obligate (100%) HP:0008236
2 increased circulating gonadotropin level 58 31 frequent (33%) Frequent (79-30%) HP:0000837
3 abnormality of secondary sexual hair 58 31 frequent (33%) Frequent (79-30%) HP:0009888
4 proportionate short stature 58 31 frequent (33%) Frequent (79-30%) HP:0003508
5 overgrowth 58 31 frequent (33%) Frequent (79-30%) HP:0001548
6 accelerated bone age after puberty 58 31 frequent (33%) Frequent (79-30%) HP:0002805
7 premature thelarche 58 31 frequent (33%) Frequent (79-30%) HP:0010314
8 acne 58 31 occasional (7.5%) Occasional (29-5%) HP:0001061
9 obesity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001513
10 prenatal maternal abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0002686
11 hypothalamic hamartoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002444
12 hydrocephalus 58 31 very rare (1%) Very rare (<4-1%) HP:0000238
13 meningitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001287
14 cafe-au-lait spot 58 31 very rare (1%) Very rare (<4-1%) HP:0000957
15 increased body weight 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Central Precocious Puberty:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 DLK1 GNRH1 IGF1 IGFBP3 KISS1 KISS1R
2 adipose tissue MP:0005375 9.91 DLK1 IGF1 IGFBP3 KISS1 KISS1R LEP
3 endocrine/exocrine gland MP:0005379 9.88 GNRH1 IGF1 IGFBP3 KISS1 KISS1R LEP
4 integument MP:0010771 9.8 GNRH1 IGF1 IGFBP3 KISS1 KISS1R LEP
5 liver/biliary system MP:0005370 9.73 DLK1 GNRH1 IGFBP3 KISS1 KISS1R LEP
6 renal/urinary system MP:0005367 9.55 GNRH1 IGF1 KISS1 KISS1R LEP
7 reproductive system MP:0005389 9.43 DLK1 GNRH1 IGF1 KISS1 KISS1R LEP
8 skeleton MP:0005390 9.1 DLK1 GNRH1 IGF1 IGFBP3 KISS1R LEP

Drugs & Therapeutics for Central Precocious Puberty

Drugs for Central Precocious Puberty (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
3 Hormone Antagonists Phase 4
4 Prolactin Release-Inhibiting Factors Phase 4
5 Hormones Phase 4
6 Antineoplastic Agents, Hormonal Phase 4
7 Contraceptive Agents Phase 4
8 Central Nervous System Stimulants Phase 4
9
Megestrol Phase 4 3562-63-8 19090 3080587
10 Contraceptives, Oral Phase 4
11 Pharmaceutical Solutions Phase 3
12 Triptorelin Pamoate Phase 3
13 Tin Fluorides

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
2 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
3 The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
4 A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Completed NCT03316482 Phase 4 Leuplin DPS 11.25mg
5 Multi-site Study of Comprehensive Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
6 An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty Completed NCT02427958 Phase 4 Leuprorelin
7 Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine Recruiting NCT03963752 Phase 4 Ziyinxiehuo Granules Herbs;Megestrol Acetate Tablet;Leuprorelin Acetate 3.75mg Injection
8 A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty Completed NCT00635817 Phase 3 Leuprolide acetate 11.25 mg;Leuprolide acetate 30 mg
9 Study of Lupron Depot In The Treatment of Central Precocious Puberty Completed NCT00660010 Phase 3 Lupron (leuprolide acetate)
10 An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty Completed NCT01467882 Phase 3 Triptorelin
11 An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty Completed NCT02452931 Phase 3 Leuprolide Acetate 45 mg
12 Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls. Completed NCT01278290 Phase 3
13 Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty Completed NCT00779103 Phase 3 Histrelin Subcutaneous Implant
14 A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty Completed NCT00667446 Phase 3 Leuprolide Acetate 3 Month Depot
15 A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP) Active, not recruiting NCT03695237 Phase 3 Leuprolide Acetate (LA)
16 An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty Not yet recruiting NCT04736602 Phase 3 Triptorelin pamoate 15mg
17 Influence of Early Adiposity Rebound, Genetic Polymorphisms and GnRHa Treatment on Long-term Outcome of Girls With Idiopathic Central Precocious Puberty. Unknown status NCT02790112
18 An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty Completed NCT02993926 Enantone;GnRH agonist
19 Markers of Adequate Pubertal Suppression During Supprelin LA Therapy for Central Precocious Puberty Terminated NCT02006680

Search NIH Clinical Center for Central Precocious Puberty

Genetic Tests for Central Precocious Puberty

Genetic tests related to Central Precocious Puberty:

# Genetic test Affiliating Genes
1 Central Precocious Puberty 29

Anatomical Context for Central Precocious Puberty

MalaCards organs/tissues related to Central Precocious Puberty:

40
Pituitary, Testes, Pineal, Ovary, Brain, Breast, Bone

Publications for Central Precocious Puberty

Articles related to Central Precocious Puberty:

(show top 50) (show all 1142)
# Title Authors PMID Year
1
Molecular Screening of MKRN3, DLK1, and KCNK9 Genes in Girls with Idiopathic Central Precocious Puberty. 6 61
28672280 2017
2
Mutations in the maternally imprinted gene MKRN3 are common in familial central precocious puberty. 61 6
26431553 2016
3
Central precocious puberty caused by mutations in the imprinted gene MKRN3. 61 6
23738509 2013
4
A GPR54-activating mutation in a patient with central precocious puberty. 6 61
18272894 2008
5
Do Most 7- to 8-Year-Old Girls with Early Puberty Require Extensive Investigation and Treatment? 61
33276126 2021
6
Central precocious puberty: recent advances in understanding the etiology and in the clinical approach. 61
33797780 2021
7
Psychiatric disorders, peer-victimization, and quality of life in girls with central precocious puberty. 61
33611071 2021
8
Diagnosis and management of precocious sexual maturation: an updated review. 61
33745030 2021
9
MKRN3-mediated ubiquitination of Poly(A)-binding proteins modulates the stability and translation of GNRH1 mRNA in mammalian puberty. 61
33744966 2021
10
Short-term effects of gonadotropin-releasing hormone analogue treatment on leptin, ghrelin and peptide YY in girls with central precocious puberty. 61
33655737 2021
11
A Comparison of Patients with Central Precocious Puberty Who Have a Pubertal versus Prepubertal Ultrasensitive LH at Presentation. 61
33765678 2021
12
Genotype-Phenotype Correlations in Central Precocious Puberty Caused by MKRN3 Mutations. 61
33383582 2021
13
Diagnostic evaluation of central precocious puberty in girls. 61
33388255 2021
14
Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study. 61
33774631 2021
15
Central precocious puberty in girls: Increasing with time. 61
33676635 2021
16
Central precocious puberty in a girl with LEGIUS syndrome: an accidental association? 61
33663580 2021
17
Hypothalamic-pituitary dysfunction in alternating hemiplegia of childhood. 61
33756210 2021
18
A case of neuronal ceroid lipofuscinosis type 8 associated with central precocious puberty. 61
33694307 2021
19
POU1F1 mutations in combined pituitary hormone deficiency: differing spectrum of mutations in a Western-Indian cohort and systematic analysis of world literature. 61
33742319 2021
20
The incidence of brain lesions in central precocious puberty: The main cause for Chinese boys was idiopathic. 61
33721341 2021
21
Cranial MRI abnormalities and long-term follow-up of the lesions in 770 girls with Central Precocious Puberty. 61
33765130 2021
22
Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty. 61
33668206 2021
23
Altered nitric oxide induced by gut microbiota reveals the connection between central precocious puberty and obesity. 61
33634977 2021
24
Is surgery effective for treating hypothalamic hamartoma causing isolated central precocious puberty? A systematic review. 61
33641048 2021
25
Hypothalamic-Pituitary Dysfunction - Part 2: Hypothalamic-Pituitary Dysfunctions Other Than Growth Hormone Deficiency in Cancer Survivors. 61
33556939 2021
26
Novel compound heterozygous mutations of PCNT gene in MOPD type II with central precocious puberty. 61
33016782 2021
27
High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. 61
33621126 2021
28
Buserelin Inhibits the Immunosuppressive Activity of Regulatory T Cells through the Protein Kinase A Signaling in a Central Precocious Puberty Model. 61
33586576 2021
29
Central precocious puberty may be a manifestation of endocrine dysfunction in pediatric patients with mitochondrial disease. 61
32914201 2021
30
Noninvasive radiomics-based method for evaluating idiopathic central precocious puberty in girls. 61
33596690 2021
31
Clinical data and basal gonadotropins in the diagnosis of central precocious puberty in girls. 61
33416514 2021
32
Prevalence and clinical characteristics of isolated forms of central precocious puberty: a cohort study at a single academic center. 61
33156813 2021
33
Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth. 61
33614957 2021
34
Overexpression of p53 accelerates puberty in high-fat diet-fed mice through Lin28/let-7 system. 61
32996351 2021
35
Time Points for Gonadotropin-Releasing Hormone Stimulation Test Results in Korean Children. 61
33445515 2021
36
Serum Irisin Levels in Central Precocious Puberty and Its Variants. 61
33034623 2021
37
Serum level of NPTX1 is independent of serum MKRN3 in central precocious puberty. 61
33180049 2021
38
Effectiveness of basal LH in monitoring central precocious puberty treatment in girls. 61
33189082 2021
39
Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty? 61
33460480 2021
40
Molecular screening of PROKR2 gene in girls with idiopathic central precocious puberty. 61
33413516 2021
41
Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis. 61
33387371 2021
42
Insights from the genetic characterization of central precocious puberty associated with multiple anomalies. 61
33313884 2021
43
Relationship between growth velocity and change of levels of insulin-like growth factor-1, insulin-like growth factor binding protein-3 and, IGFBP-3 promoter polymorphism during GnRH agonist treatment. 61
32871648 2020
44
Clinical impact of hypothalamic-pituitary disorders after conformal radiation therapy for pediatric low-grade glioma or ependymoma. 61
33037871 2020
45
Idiopathic central precocious puberty in a Klinefelter patient: highlights on gonadotropin levels and pathophysiology. 61
33292161 2020
46
Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty. 61
33292495 2020
47
Precocious puberty in a girl with 3-methylglutaconic aciduria type 1 (3-MGA-I) due to a novel AUH gene mutation. 61
33304818 2020
48
Delayed and Precocious Puberty: Genetic Underpinnings and Treatments. 61
33153677 2020
49
Rasmussen's encephalitis and central precocious puberty. Neuroendocrinological characterization of three cases. 61
33126087 2020
50
Machine learning identifies girls with central precocious puberty based on multisource data. 61
33623892 2020

Variations for Central Precocious Puberty

ClinVar genetic disease variations for Central Precocious Puberty:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MKRN3 NM_005664.4(MKRN3):c.637del (p.Arg213fs) Deletion Pathogenic 56901 rs879255238 GRCh37: 15:23811565-23811565
GRCh38: 15:23566418-23566418
2 MKRN3 NM_005664.4(MKRN3):c.1172dup (p.Tyr391Ter) Duplication Pathogenic 56902 rs879255239 GRCh37: 15:23812100-23812101
GRCh38: 15:23566953-23566954
3 MKRN3 NM_005664.4(MKRN3):c.1095G>T (p.Arg365Ser) SNV Pathogenic 56903 rs879255240 GRCh37: 15:23812024-23812024
GRCh38: 15:23566877-23566877
4 MKRN3 NM_005664.4(MKRN3):c.482dup (p.Ala162fs) Duplication Pathogenic 56904 rs763195944 GRCh37: 15:23811404-23811405
GRCh38: 15:23566257-23566258
5 MKRN3 NM_005664.4(MKRN3):c.982C>T (p.Arg328Cys) SNV Pathogenic 438339 rs1264639964 GRCh37: 15:23811911-23811911
GRCh38: 15:23566764-23566764
6 KISS1R NM_032551.5(KISS1R):c.1157G>C (p.Arg386Pro) SNV Pathogenic 5760 rs121908499 GRCh37: 19:920708-920708
GRCh38: 19:920708-920708
7 KISS1R NM_032551.5(KISS1R):c.305T>C (p.Leu102Pro) SNV Likely pathogenic 5759 rs104894703 GRCh37: 19:918604-918604
GRCh38: 19:918604-918604
8 MKRN3 NM_005664.4(MKRN3):c.326G>A (p.Cys109Tyr) SNV Likely pathogenic 625144 rs1566764505 GRCh37: 15:23811255-23811255
GRCh38: 15:23566108-23566108
9 MKRN3 NM_005664.4(MKRN3):c.103T>G (p.Cys35Gly) SNV Uncertain significance 1030007 GRCh37: 15:23811032-23811032
GRCh38: 15:23565885-23565885
10 KISS1R NM_032551.5(KISS1R):c.439C>T (p.Pro147Ser) SNV Uncertain significance 800826 rs61735615 GRCh37: 19:919559-919559
GRCh38: 19:919559-919559

Expression for Central Precocious Puberty

Search GEO for disease gene expression data for Central Precocious Puberty.

Pathways for Central Precocious Puberty

GO Terms for Central Precocious Puberty

Cellular components related to Central Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 LEP KISS1 IGFBP3 IGF1 GNRH1 GH1
2 extracellular space GO:0005615 9.63 LEP IGFBP3 IGF1 GNRH1 GH1 DLK1
3 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
4 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Central Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 9.5 LEP IGFBP3 IGF1
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 LEP IGF1 GH1
3 positive regulation of JAK-STAT cascade GO:0046427 9.37 LEP GH1
4 bone mineralization involved in bone maturation GO:0035630 9.16 LEP IGF1
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 LEP IGF1 GH1
6 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.8 IGFBP3 IGF1 GH1

Molecular functions related to Central Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 LEP IGF1 GNRH1 GH1

Sources for Central Precocious Puberty

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....